Efficacy of estriol in inhibiting epithelial proliferation in mammary fibroadenoma: randomized clinical trial.
OBJECTIVE
Mammary fibroadenoma is a disease that affects a large number of women of reproductive age. The aim of this study was to evaluate the proliferative activity of mammary fibroadenoma through expression of Ki-67 and c-myc antigens, following administration of oral contraceptive with or without estriol.


METHODS
Placebo-controlled double-blind randomized clinical trial in the Mastology Sector of the Department of Gynecology, Universidade Federal de São Paulo.


METHODS
Thirty-three fibroadenoma patients were studied. Ten women (group 1) took an oral contraceptive constituted by levonorgestrel and ethinyl estradiol together with placebo manufactured in the same capsule for four consecutive cycles with a seven-day interval between them. The other 23 patients (group 2) took the same oral contraceptive together with estriol, which was put into the same capsule and used in the same way as among the group 1 patients. After four cycles, the nodules were surgically removed and sent for immunohistochemical analysis of Ki-67 and c-myc expression.


RESULTS
The Ki-67 and c-myc analysis did not reveal any significant differences between the study groups. The values were 9.16 and 10.54 for group 1 and 10.86 and 17.03 for group 2, respectively. There was a tendency towards higher expression of antigens in group 2.


CONCLUSIONS
Our results showed that there was no significant statistical difference in Ki-67 and c-myc expression between our study groups, but only a tendency towards higher expression among users of oral contraceptives containing estriol.
Estevão
Rodrigo Augusto Fernandes
RA
Department of Gynecology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil. rodrigoestevao@terra.com.br
Baracat
Edmund Chada
EC
Logullo
Angela Flávia
AF
Oshima
Celina Tizuko Fujiyama
CT
Nazário
Afonso Celso Pinto
AC
D000328:Adult; D001706:Biopsy; D001943:Breast Neoplasms / Q000378:metabolism / Q000473:pathology*; D049109:Cell Proliferation / Q000187:drug effects; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects / Q000494:pharmacology*; D004311:Double-Blind Method; D004847:Epithelial Cells / Q000187:drug effects*; D004964:Estriol / Q000009:adverse effects / Q000494:pharmacology*; D004997:Ethinyl Estradiol / Q000009:adverse effects; D005260:Female; D018226:Fibroadenoma / Q000378:metabolism / Q000473:pathology*; D016259:Genes, myc / Q000502:physiology; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000032:analysis* / Q000378:metabolism; D016912:Levonorgestrel / Q000009:adverse effects; D042361:Mammary Glands, Human / Q000187:drug effects; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D013194:Staining and Labeling; D055815:Young Adult
D003277:Contraceptives, Oral, Combined; D019394:Ki-67 Antigen; D018809:Proliferating Cell Nuclear Antigen; D004997:Ethinyl Estradiol; D016912:Levonorgestrel; D004964:Estriol